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Guidance on Contingency Planning for People who use Drugs and 
COVID-19 
 
26/03/2020 
 
Developed by the HSE for anyone who is working with people who use drugs (PWUD) including those 
on OST.  
 
 
Disclaimer COVID-19 is a rapidly evolving pandemic with national advice and guidance updated 
regularly. This document is accurate at the point of publication and will be reviewed regularly and 
updates issued as and when required. 
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Concerns 
 People who are not on OST currently and may need to be commenced. 
 Naloxone provision. 
 People’s ability to acquire top up drugs may be limited. 
 People may be rough sleeping or using one-night-only accommodation, hostels, B&Bs and 
hotels and may not be able to self-isolate if required. 
 People may be stockpiling drugs, increasing risk of overdose. 
 People may be self-isolating and using alone, increasing risk of overdose. 
 There may be polydrug use including alcohol and non-prescribed prescription medications. 
 Covid-19 is a respiratory illness with possibility of respiratory depression. 
 Many people may find isolation and quarantine intolerable and may have difficulty co-
operating. 
 People may not have sufficient access to clean injecting equipment due to limited access to 
needle exchange or due to isolation.  
 People who do not attend the prescriber or pharmacy as planned. 
 Harm reduction advice to people who use drugs. 
Actions 
Identification  
 Urgently identify homeless people and others on waiting lists in need of drug treatment. 
Aim to get all clients awaiting OST into treatment promptly in order to minimise their risks to 
self and to others in the current Covid-19 crisis. Staff working in drug services, homeless 
services and social inclusion-specific testing services all have a role in identifying people 
needing OST. 
Information 
 Ensure that all prescribing locations including Level 1 and Level 2 GPs gather up-to-date 
contact details, dose details and dispensing clinic/pharmacy details for all clients on OST. 
This information should be stored in line with GDPR guidelines and in a manner that would 
be accessible should a clinic/GP practice need to close. 
Induction of new clients on OST during COVID-19 crises 
 
As outlined in the OST guidelines it may not be necessary to go through a prolonged assessment 
process in the following circumstances, which are also relevant to rapid/emergency induction: 
 the person is a known opioid dependent person through engagement with the service. 
 there are track marks are visible. 
 the person has a previous history and has been on OST treatment before - this can be 
verified through CTL as necessary. 
 the person is/was in treatment in another jurisdiction. 
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Process: 
 Clinical review is important and can take place via video link on a smartphone with a Level 2 
GP. Opioid presence can be confirmed with point of care testing.  Please see communication 
issued by the ICGP to Level 1 and Level 2 GPs in appendix 1. 
 Client sends a photo of themselves to the GP via Smartphone. 
 GP completes CTL template form and attach a clear photo to CTL via Healthmail or HSE email 
to centraltreatmentlist.gp@healthmail.ie. 
 Liaise with relevant GP coordinator (see appendix 2). 
 Liaise with pharmacy co-ordinator (see appendix 3). 
 Treatment card issued from CTL electronically. 
 Induction on OST in line with the OST guidelines. 
 An initial 20mg of methadone can be prescribed to the individual after clinical assessment to 
commence the induction process. 
Emergency induction of OST is likely to be required when a person with opioid addiction is required 
to enter isolation due to possible or confirmed COVID 19 infection.  
In certain circumstances the clinician may be unsure about the safety of commencing, please refer to 
list of GP coordinators in appendix 2 for further advice.  
Please note: Unlike our usual policies for managing waiting lists and commencing clients on 
treatment, we may have to deviate from these policies during the current crisis in order to ensure the 
safety of the client and to fulfil the public health requirements for minimising viral transmission.   
Medication Choice 
There is a risk/benefit balance to be struck in terms of whether to commence the client on 
methadone or buprenorphine/naloxone. If there is a designated family member who could safely 
supervise the doses at home in the event of a lockdown situation then this may be a factor in 
choosing the appropriate medication. 
Buprenorphine/naloxone may be a preferable option within a clinic setting if the person does not 
need to self-isolate. Contact must be made with the liaison pharmacist to check the availability of a 
dispensing pharmacy and to check the capacity to supervise buprenorphine/naloxone in the current 
situation before a decision is made about medication and before the client leaves the clinic. 
The following considerations may determine which to choose in each individual case:   
                                                         METHADONE 
PROS CONS 
 1.       Methadone involves less supervision time 
for pharmacist 
2.       No need to wait for withdrawals to 
commence 
3.       GPs are more familiar with induction or 
methadone  
 1.      Induction to optimum dose is slower 
2.       Methadone is less safe if take away doses 
are required particularly early in the induction 
phase 
3.       Less safe if polydrug use is an issue 
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                                                      BUPRENORPHINE 
PROS CONS 
 1.       Buprenorphine is a safer medication to 
take home in the event that a lockdown 
situation arises 
2.       buprenorphine can be titrated to optimum 
dose faster 
3.       safer medication where overdose is a risk 
consideration 
1.       Supervision of Buprenorphine takes more 
contact time for the pharmacist 
2.       Client will be in the pharmacy building for 
longer 
3.       Client needs to be in withdrawals to 
commence treatment 
  
 
Naloxone for people using opioid drugs 
Naloxone is a medicine recommended by the World Health Organisation for treatment in opioid 
overdose cases. Within minutes, it reverses the effects of opioid overdose. Naloxone is a 
prescription-only medication. GPs can prescribe Naloxone to a person who is at risk of overdosing on 
opioids. The GP can dispense the naloxone and will explain to the client how it should be used. 
Naloxone can be obtained by GPs who intend to prescribe this by contacting the HSE National Social 
Inclusion Office [appendix 3]. 
Every individual in receipt of OST and in contact with treatment providers should be offered and 
encouraged to take a supply of Naloxone. 
Naloxone should be administered by a person trained in using the product. In the current crisis, 
consider using injectable Naloxone. If using intranasal product, use precautions including gloves 
taking care to wash hands thoroughly after. Used product should be disposed of within sharps bins 
using the normal protocols. 
OST Provision 
OST for person in isolation at home  
Follow all public health advices on minimising viral transmission 
If the person is already on treatment, the following options can be considered for the on-going 
management of their OST: 
 Clinical review is important and can take place via video link on a smartphone. 
 Option 1: The provision of take away doses for the duration (or part) of the self- isolation.  
 Option 2: The provision of medication to a responsible family member following consent 
from the client. 
 Option 3: The provision of medication by a driver and a clinical person/key worker. Inform 
the client in advance that a photograph will be taken using a mobile phone by the person 
delivering the medication. This is to ensure the correct person is receiving the medication 
and avoid the need for a signature for receipt of same. 
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 If no paper prescription is available, PCRS have confirmed that a scanned copy of the 
prescription can be transmitted from the clinic/GP to the pharmacy via Healthmail. This can 
then be followed up by a postal copy. 
 A scanned copy of the ID of the designated person should be sent to the pharmacy in 
advance of the pick up particularly if the pharmacy are not familiar with the person along 
with completed nominated person template in appendix 5. The designated person will need 
to show ID to the pharmacist. 
 Advice on the safe storage of medications must be given to the client, refer to HSE leaflet on 
storage of methadone at home. 
If the person is not on OST treatment, please see section on induction of new clients on OST during 
COVID-19 crises. 
 
OST for person in a residential facility including isolation hub and homeless 
accommodation  
Please see the Guidance for Vulnerable Group Settings on the HSPC website.  
If the person is already on treatment, ensure adequate and safe supplies of medication. The 
following should be taken into consideration: 
 Safe and secure storage of medication including the presence of a small safe.  
 Where clients are residing with family, advice on the safe storage of medications must be 
given to the client, refer to HSE leaflet on storage of methadone. 
 Accurate records of client details including dose. 
 Risk of take-out doses to other residents. 
 Contact the local HSE addiction service for support in managing any remaining medication 
should a client leave the isolation hub (either as a result of a negative test or transfer to 
another facility/back to homeless accommodation).  
If the person is not on OST treatment, please see section on induction of new clients on OST during 
COVID-19 crises. 
 
OST for person in hospital 
 Refer to Clinical Guidelines for Opioid Substitution Treatment: guidance document for OST in 
the hospital setting. 
People who use Benzodiazephines and/or Alcohol 
Benzodiazepine 
There may be people who report use of benzodiazepines but who do not have a prescription for 
same. This can be determined by self-report, clinical assessment and confirmed by point of care or 
laboratory testing. 
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To avoid benzodiazepine withdrawal symptoms, GPs are advised to commence the person on a 
maximum dose of 30 mgs per day in divided doses using 2mgs tablets. This should facilitate the 
patient remaining in self-isolation. 
It should however be made clear to the client and should be documented that such treatment is for 
the duration of the isolation only.  However, a brief tapering prescription of daily dispensed meds 
might be considered on discharge-at the discretion of the responsible clinician. 
Information in relation to the management of benzodiazepine use in the longer term is available 
from the Medicines Management Programme. 
Alcohol 
People with alcohol use disorder may present with alcohol withdrawal symptoms. GPs are advised of 
the following: 
 The use of a benzodiazepine such as diazepam or chlordiazepoxide is recommended to 
manage alcohol withdrawals in the community. A useful article is available here. 
 NICE guidelines advise the following: 
• In a fixed-dose regimen, titrate the initial dose of medication to the severity of 
alcohol dependence and/or regular daily level of alcohol consumption.  
• In severe alcohol dependence higher doses will be required to adequately control 
withdrawal and should be prescribed according to the SMPC. Make sure there is 
adequate supervision if high doses are administered. Gradually reduce the dose of 
the benzodiazepine over 7–10 days to avoid alcohol withdrawal recurring. 
• Vitamin supplementation should be considered in those at risk of developing 
Wernicke's encephalopathy. 
• For people who typically drink over 15 units of alcohol per day, and/or who score 
20 or more on the AUDIT, consider offering: 
 an assessment for and delivery of a community-based assisted withdrawal, 
to include vitamin supplementation if necessary  
or 
 assessment and management in specialist alcohol services if there are safety 
concerns about a community-based assisted withdrawal. 
Community Pharmacy  
 
Disruption to dispensing 
In the event of closure of a community pharmacy: 
 Community pharmacies should contact the Liaison Pharmacist so they can assist in co-
ordinating the transfer and liaising with GPs/clinics to ensure all clients are made aware of 
the pharmacy change.  Active prescriptions should be transferred form the closed pharmacy 
and will need to be continued until the next scheduled prescription from the GP. 
Prescriptions from the closed pharmacy should clearly indicate if emergency take-away 
doses have been given to the client at the discretion of the pharmacist, e.g. due to isolation.  
8 
 
 If a large number of clients are being transferred the new pharmacy may need to requisition 
OST medicines from the closed pharmacy (if feasible), in order to obtain more stock if there 
is a delay in wholesaler ordering and delivery.  
 Communication issued from the HSE Liaison Pharmacists to community pharmacies 
dispensing Methadone/Buprenorphine to OST clients can be found here. 
 In the event that a pharmacy cannot supervise doses in the consultation room, every 
consideration should be given to preserve the client’s privacy while consuming their dose. If 
this cannot be facilitated please contact the Liaison Pharmacist. 
Disruption to prescribing service 
In the event of a GP prescriber or practice having to close, the following steps should be taken: 
 Inform the relevant GP Co-ordinator at the earliest possible convenience. Have an up to date 
list of OST clients with their contact details and doses available on request. 
 If possible identify a practice or close colleague who may be able to prescribe in the GPs 
absence. 
 If no local arrangement possible alternative prescribing will be facilitated by the relevant GP 
Co-ordinator. 
 Continuity of medication must be prioritised.  
Communication with people who use drugs 
The need for appropriate social distancing in the clinic/pharmacy setting should be highlighted to 
clients. General advice on COVID-19 can be found on the HSE website  
Guidance for healthcare professionals can be found on the Health Protection Surveillance Centre 
website 
Advice for people who use drugs can be found on drugs.ie  
COVID-19 avoidance strategies should be routinely promoted to clients through all Injecting 
Equipment Provision services. Staff should also communicate the increased risk of transmission if 
sharing smoking/inhalation equipment. All staff should continue to promote the HSE advice on social 
distancing, hand washing and cough etiquette. 
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Appendix 1 Letter to Level 1 and Level 2 GPS from the ICGP 
 
 
 
 
March 13th, 2020 
 
URGENT COMMUNICATION REGARDING OST PATIENTS 
 
To all Level 1 and Level 2 GPs 
Dear Colleagues, 
Following the advice provided by ECDC yesterday, we need to make every effort to ensure the 
safety of ourselves, our staff, our pharmacy colleagues as well as the safety of our patients. We 
manage a vulnerable cohort of patients and as you will appreciate, it will be a challenge to get that 
balance exactly right. However, in conjunction with the HSE and our Public Health colleagues, we 
would like to recommend the following guidelines: 
 
1. For each patient in your care, assess the need for the patient to attend in person at 
your surgery/clinic. Where possible do follow up consultations electronically or by 
telephone. 
 
2. Assess the safest dispensing requirements for the patient. Where possible; 
 
 Minimise the number of pharmacy attendances 
 Give the maximum number of take away doses having given due consideration to 
the safety of the patient 
 Engage the help of a family member where necessary to assist with the safe 
management of medication particularly if patient is getting more take away doses than 
usual. 
 
3. Consider giving the patient and/or the designated family member the following leaflet on 
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the safe storage of methadone: 
https://www.hse.ie/eng/about/who/primarycare/socialinclusion/homelessness-and- 
addiction/addiction-treatment-and-rehabilitation/keeping-children-safe.pdf 
 
4. Consider giving patients a copy of the methadone leaflet to remind them of the risks 
associated with methadone: http://www.drugs.ie/drugtypes/drug/methadone_opiate 
 
5. Individuals who have symptoms suggestive of Covid-19 should self-isolate for a period of 14 
days. Additional measures will need to be put in place to ensure safe delivery of medication 
for these individuals. This may involve a family member collecting medication or a pharmacy 
delivery if that remains the only option. 
 
6. Viral testing for symptomatic individuals should follow arrangements which are in place 
in your local area. These arrangements are likely to change as it is an evolving situation 
and it is important that the local arrangements are followed. 
 
In this time of unprecedented challenges and the uncertainty about how the Covid-19 situation will 
evolve, we as practitioners need to apply our best clinical judgement on a case-by-case basis. We 
will not be in a position to rigidly apply our existing guidelines and work practices – there needs to 
be appropriate flexibility in their application. 
 
We will be in regular contact with our HSE and Public Health colleagues on these matters and we 
will keep you briefed on the evolving situation. In the meantime should you have any queries, 
please contact the GP Co-ordinator for your area: 
 
North Dublin City: Dr Des Crowley, des.crowley@hse.ie, 083-1058809 
North Dublin: Dr Hugh Gallagher, hugh.gallagher@hse.ie, 087-9327972 
South Dublin and County Kildare: Dr Margaret Bourke, margaret.bourke@hse.ie, 086-
0222704, 014767010 (Castle St Clinic) 
National Co-ordinator (all areas outside Dublin): Dr Ide Delargy, 
info@gpblackrock.com, 086-8100803 
 
Please look after yourselves and your staff during these challenging times. 
Kind regards, 
 
 
Dr Ide Delargy 
Director, ICGP Addiction Management in Primary Care Programme 
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Dr Des Crowley 
Assistant Director, ICGP Addiction Management in Primary Care Programme 
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Appendix 2 GP Liaison contact details 
 
Area Contact 
West Dublin and South Side (D2, D4 
Ringsend only, D6, D8, D12, D16, D24) 
Co Kildare 
East Coast (Dún Laoghaire, South 
County Dublin, Wicklow) 
Dr. Margaret Bourke margaret.bourke@hse.ie 
0860222704 
Dublin North City (Fairview, 
Blanchardstown, North Strand, 
Thompson Centre, Dublin1) 
Dr. Des Crowley des.crowley@hse.ie 0879327972 
Dublin North County (Drumcondra, 
Ballymun, Finglas, Skerries, Swords) 
Dr. Hugh Gallagher hugh.gallagher@hse.ie 0872198094 
All areas outside of Dublin Dr. Ide DeLargy info@gpblackrock.com  
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Appendix 3 Pharmacy Liaison contact details 
 
 
Area Contact 
Dublin South city and county, Kildare 
and Wicklow 
James Kee james.kee@hse.ie 0877068013 
Helen Johnston helen.johnston@hse.ie  0868543733 
Dublin North City and County Blaithin Cotter blaithin.cotter@hse.ie 087 7068013 
All areas outside of Dublin Norma Harnedy NormaM.Harnedy@hse.ie 0868397159 
  
14 
 
Appendix 4 HSE Addiction Service Managers contact details 
 
CHO AREA CONTACT 
CHO1 Donegal Cora McAleer cora.mcaleer@hse.ie   
 Sligo/Leitrim/West Cavan Martin Jones martin.jones@hse  
 Cavan/Monaghan Trish Garland patricia.garland@hse.ie  
CHO2 Galway, Roscommon, Mayo Shane McGuire shane.mcguire@hse.ie   
CHO3 Clare, Limerick, North 
Tipp/East Limerick 
Rory Keane rory.keane1@hse.ie  
  Tony Quilty tony.quilty@hse.ie  
CHO4 Cork, Kerry David Lane david.lane1@hse.ie 
  Rebecca Loughry rebecca.loughry@hse.ie 
CHO5 South Tipp, Carlow, Kilkenny, 
Waterford, Wexford 
Paul Goff paul.goff@hse.ie  
  Jeanne Hendrick Jeanne.Hendrick@hse.ie 
CHO6&7  Louise Ann DEVLIN  Louise.devlin@hse.ie  
  Concepta DeBrun Concepta.DeBrun@hse.ie 
  Justin Parkes Justin.Parkes@hse.ie 
CHO8 Laois, Longford, Offaly, 
Westmeath 
Fran Byrne fran.byrne@hse.ie 
 Louth Meath Michelle Keaveney Michelle.Keaveney@hse.ie 
CHO9  Lorraine Brown lorraine.brown@hse.ie 
  Donal Cassidy gmsidncc gmsidncc@hse.ie  
NDTC National Drug Treatment 
Centre 
williamh.ebbitt1@hse.ie 
CTL Central Treatment List 
operational queries 
ctl@dtcb.ie 
Liaison National Pharmacy liaison NormaM.Harnedy@hse.ie 
 National GP liaison idedelargy@gmail.com 
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SI National Social Inclusion Office eamon.keenan@hse.ie 
  Nicola.corrigan@hse.ie                                                             
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Appendix 5 Letter to pharmacy re designated person 
 
 
Emergency Measures as a result of COVID 19 
 
Dear Pharmacist, 
A client whom you dispense methadone for is now in isolation and cannot call to the pharmacy for 
daily supervision of their Methadone/buprenorphine dose.  
Given these exceptional circumstances it is necessary for a designated person to collect their 
medication and deliver for administration in the clients’ place of isolation. It may also be necessary 
for their prescription to be sent by electronic means such as Healthmail. 
It would be extremely helpful if the medication could be ready for collection by 10am each day 
(subject to local arrangement). 
 
Client name DOB Designated person picking up medication 
   
   
   
   
   
   
   
   
 
Many thanks and kind regards, 
 
Clinic stamp/GP authorisation 
